Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search


AFT Pharmaceuticals on track to return to profitability

AFT Pharmaceuticals, manufacturer of the Maxigesic painkiller, significantly shrunk its first half loss to $0.1million from $6.7 million in the prior period, saying it remains on track to return to profitability in this financial year.

The company says the small Operating Loss in the six months to September 30 2018 is positive progress and it expects the second half of the financial year to generate greater revenues and profitability.

The improvement in operating loss came from strong growth in Gross Profit (up 24% to $17.8 million) and reduced Research and Development costs, as clinical trial programmes identified at the time of AFT’s 2015 IPO are concluding. Research and Development investment reduced to $2.2 million, from $5.0 million in the previous corresponding six month period.

Completion of Research and Development programmes allows AFT to commence regulatory filings for new Maxigesic products which will support future revenue growth — an intravenous version for hospital use and an oral liquid for use in children. Additional Maxigesic dose forms, hot drink sachets and dry stick sachets, are also in development and regulatory filings for these are expected to commence in 2019.

AFT’s Total Income in the first half of FY19 was $40.2 million, up 7% from $37.4 million in the prior period. This was largely driven by continued growth in the Australian and Rest of World markets.

Maxigesic sales in Australia in the six months to September 30 doubled versus the prior period, after an Australian regulatory change restricted codeine-based painkillers to prescription-only from February 2018. Maxigesic is a codeine-free painkiller containing ibuprofen and paracetamol.

AFT founder and Chief Executive Hartley Atkinson said: “Maxigesic has obtained a market leadership position in Australia for paracetamol-ibuprofen combinations. We see the opportunity of significant ongoing organic growth from Maxigesic tablets and additional dose forms such as Maxigesic IV and Maxigesic Oral Liquid, which are planned to be launched in the next 12-18 months.”

Revenue growth in the six month period also came in the Rest of World market, up 70% on the prior period to $2.8 million, and Southeast Asia, up 81% on the prior period to $1.1 million. New Zealand revenue declined, down 11% to 12.6 million, however sales of higher margin products saw a 23% increase in its Gross Profit.

Maxigesic is now being sold in 15 countries and is licensed in 128, up from 125 in the 2018 financial year. The company says the timing of sales in different parts of the world remains difficult to determine due to the multitude of countries and different regulatory requirements, however estimates from licensees continue to indicate that sales will increase significantly over the next few years, with new launches, growth in already launched markets, and new line extensions.

© Scoop Media

Business Headlines | Sci-Tech Headlines


Grey Power: Is Disappointed To Learn Of More Bank Closures

Many older people are being left without essential services because of cost cutting and the march of modern technology. It is now expected that most banking transactions can occur via the internet or telephone. Jan Pentecost, President of the Grey Power ... More>>


Economy: Supply Chain On Brink Of Overload Says National Road Carriers

The New Zealand supply chain is on the brink of overload and it looks like the upcoming peak imports season may push it over the edge says National Road Carriers Association (NRC) CEO David Aitken. “Worldwide supply chains are in disarray,” says Mr Aitken. ... More>>

Retail: Supermarkets Announced As Government’s Second Market Study

The Government has today launched a market study to ensure New Zealanders are paying a fair price for groceries. More>>


Statistics New Zealand: Retail Sales Recover In The September 2020 Quarter

Retail sales values recorded the largest September quarter rise since the series began in 1995, Stats NZ said today. Spending on major household items, vehicles, and groceries contributed to the strong 7.4 percent ($1.8 billion) rise in total ... More>>

Kea Aerospace: New Zealand Flies Into The Stratosphere

Development has started on a solar-powered, unmanned aircraft that can fly in the stratosphere continuously for months at a time. The zero-emission aircraft will carry a suite of imagery equipment that will be game-changing for many industries, vastly ... More>>

Stats NZ: Births And Deaths: Year Ended September 2020

Births and deaths releases provide statistics on the number of births and deaths registered in New Zealand, and selected fertility and mortality rates. Key facts For the year ended September 2020: 57,753 live births and 32,670 deaths ... More>>


Forest & Bird: Kākāpō Wins Bird Of The Year 2020

The nation has voted and Aotearoa New Zealand has a new Bird of the Year. New Zealand’s moss-colored flightless parrot has climbed to the top-spot for the second time in Forest & Bird’s annual Te Manu Rongonui o Te Tau/Bird of the Year competition. ... More>>